{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:24:45Z","timestamp":1787599485850,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00292-026-01570-x","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:50:10Z","timestamp":1779889810000},"page":"326-334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erblicher Brustkrebs","Hereditary breast cancer"],"prefix":"10.1007","volume":"47","author":[{"given":"Annette","family":"Lebeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou\u00a0AC, Foulkes\u00a0WD, Tischkowitz\u00a0M (2014) Breast-cancer risk in families with mutations in PALB2. N\u00a0Engl J Med 371:1651\u20131652","journal-title":"N Engl J Med"},{"key":"1570_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/jmedgenet-2012-101472","volume":"50","author":"PR Benusiglio","year":"2013","unstructured":"Benusiglio\u00a0PR, Malka\u00a0D, Rouleau\u00a0E et\u00a0al (2013) CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J\u00a0Med Genet 50:486\u2013489","journal-title":"J Med Genet"},{"key":"1570_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S1470-2045(25)00152-4","volume":"26","author":"E Blondeaux","year":"2025","unstructured":"Blondeaux\u00a0E, Sonnenblick\u00a0A, Agostinetto\u00a0E et\u00a0al (2025) Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol 26:759\u2013770","journal-title":"Lancet Oncol"},{"key":"1570_CR4","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","volume":"71","author":"S Casadei","year":"2011","unstructured":"Casadei\u00a0S, Norquist\u00a0BM, Walsh\u00a0T et\u00a0al (2011) Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 71:2222\u20132229","journal-title":"Cancer Res"},{"key":"1570_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling\u00a0L, Carvalho\u00a0S, Allen\u00a0J et\u00a0al (2021) Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N\u00a0Engl J Med 384:428\u2013439","journal-title":"N Engl J Med"},{"key":"1570_CR6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ijc.32396","volume":"146","author":"C Engel","year":"2020","unstructured":"Engel\u00a0C, Fischer\u00a0C, Zachariae\u00a0S et\u00a0al (2020) Breast cancer risk in BRCA1\/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer 146:999\u20131009","journal-title":"Int J Cancer"},{"key":"1570_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8501","volume":"3","author":"S Gallagher","year":"2020","unstructured":"Gallagher\u00a0S, Hughes\u00a0E, Wagner\u00a0S et\u00a0al (2020) Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Netw Open 3:e208501","journal-title":"JAMA Netw Open"},{"key":"1570_CR8","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1053\/gast.2000.20228","volume":"119","author":"FM Giardiello","year":"2000","unstructured":"Giardiello\u00a0FM, Brensinger\u00a0JD, Tersmette\u00a0AC et\u00a0al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119:1447\u20131453","journal-title":"Gastroenterology"},{"key":"1570_CR9","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","volume":"27","author":"MK Graeser","year":"2009","unstructured":"Graeser\u00a0MK, Engel\u00a0C, Rhiem\u00a0K et\u00a0al (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J\u00a0Clin Oncol 27:5887\u20135892","journal-title":"J Clin Oncol"},{"key":"1570_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","volume":"1","author":"S Hansford","year":"2015","unstructured":"Hansford\u00a0S, Kaurah\u00a0P, Li-Chang\u00a0H et\u00a0al (2015) Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol 1:23\u201332","journal-title":"JAMA Oncol"},{"key":"1570_CR11","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cam4.1376","volume":"7","author":"J Hauke","year":"2018","unstructured":"Hauke\u00a0J, Horvath\u00a0J, Gro\u00df\u00a0E et\u00a0al (2018) Gene panel testing of 5589 BRCA1\/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer medicine 7:1349\u20131358","journal-title":"Cancer medicine"},{"key":"1570_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","volume":"177","author":"BaM Heemskerk-Gerritsen","year":"2019","unstructured":"Heemskerk-Gerritsen\u00a0BaM, Jager\u00a0A, Koppert\u00a0LB et\u00a0al (2019) Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 177:723\u2013733","journal-title":"Breast Cancer Res Treat"},{"key":"1570_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu\u00a0C, Hart\u00a0SN, Gnanaolivu\u00a0R et\u00a0al (2021) A Population-Based Study of Genes Previously Implicated in Breast Cancer. N\u00a0Engl J Med 384:440\u2013451","journal-title":"N Engl J Med"},{"key":"1570_CR14","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1158\/1055-9965.EPI-13-0745-T","volume":"22","author":"M Janatova","year":"2013","unstructured":"Janatova\u00a0M, Kleibl\u00a0Z, Stribrna\u00a0J et\u00a0al (2013) The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiol Biomarkers Prev 22:2323\u20132332","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1570_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103672","volume":"53","author":"K Kast","year":"2016","unstructured":"Kast\u00a0K, Rhiem\u00a0K, Wappenschmidt\u00a0B et\u00a0al (2016) Prevalence of BRCA1\/2 germline mutations in 21 401 families with breast and ovarian cancer. J\u00a0Med Genet 53:465\u2013471","journal-title":"J Med Genet"},{"key":"1570_CR16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker\u00a0KB, Hopper\u00a0JL, Barnes\u00a0DR et\u00a0al (2017) Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama 317:2402\u20132416","journal-title":"Jama"},{"key":"1570_CR17","unstructured":"Leitlinienprogramm Onkologie. Deutsche Krebsgesellschaft, Deutsche Krebshilfe AWMF (ed) (2026) S3-Leitlinie Fr\u00fcherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. In: Langversion 5.0, AWMF-Registernummer: 032-045OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/mammakarzinom\/. Accessed 10.3.2026"},{"key":"1570_CR18","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/hmg\/ddz027","volume":"28","author":"A Lipsa","year":"2019","unstructured":"Lipsa\u00a0A, Kowtal\u00a0P, Sarin\u00a0R (2019) Novel germline STK11 variants and breast cancer phenotype identified in an Indian cohort of Peutz-Jeghers syndrome. Hum Mol Genet 28:1885\u20131893","journal-title":"Hum Mol Genet"},{"key":"1570_CR19","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai\u00a0PL, Best\u00a0AF, Peters\u00a0JA et\u00a0al (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122:3673\u20133681","journal-title":"Cancer"},{"key":"1570_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/gepi.21971","volume":"40","author":"M Marabelli","year":"2016","unstructured":"Marabelli\u00a0M, Cheng\u00a0SC, Parmigiani\u00a0G (2016) Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk. Genet Epidemiol 40:425\u2013431","journal-title":"Genet Epidemiol"},{"key":"1570_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6744","volume":"8","author":"N Mavaddat","year":"2022","unstructured":"Mavaddat\u00a0N, Dorling\u00a0L, Carvalho\u00a0S et\u00a0al (2022) Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncol 8:e216744","journal-title":"JAMA Oncol"},{"key":"1570_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","volume":"11","author":"KA Mcbride","year":"2014","unstructured":"Mcbride\u00a0KA, Ballinger\u00a0ML, Killick\u00a0E et\u00a0al (2014) Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nature reviews Clinical oncology 11:260\u2013271","journal-title":"Nature reviews. Clinical oncology"},{"key":"1570_CR23","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/sj.onc.1209877","volume":"25","author":"H Nevanlinna","year":"2006","unstructured":"Nevanlinna\u00a0H, Bartek\u00a0J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25:5912\u20135919","journal-title":"Oncogene"},{"key":"1570_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-015-3665-z","volume":"165","author":"J Ngeow","year":"2017","unstructured":"Ngeow\u00a0J, Sesock\u00a0K, Eng\u00a0C (2017) Breast cancer risk and clinical implications for germline PTEN mutation carriers. Breast Cancer Res Treat 165:1\u20138","journal-title":"Breast Cancer Res Treat"},{"key":"1570_CR25","first-page":"6643","volume":"63","author":"M Olivier","year":"2003","unstructured":"Olivier\u00a0M, Goldgar\u00a0DE, Sodha\u00a0N et\u00a0al (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643\u20136650","journal-title":"Cancer Res"},{"key":"1570_CR26","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/jnci\/djt277","volume":"105","author":"R Pilarski","year":"2013","unstructured":"Pilarski\u00a0R, Burt\u00a0R, Kohlman\u00a0W et\u00a0al (2013) Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J\u00a0Natl Cancer Inst 105:1607\u20131616","journal-title":"J Natl Cancer Inst"},{"key":"1570_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3369","volume":"14","author":"K Rhiem","year":"2012","unstructured":"Rhiem\u00a0K, Engel\u00a0C, Graeser\u00a0M et\u00a0al (2012) The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 14:R156","journal-title":"Breast Cancer Res"},{"key":"1570_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson\u00a0ME, Tung\u00a0N, Conte\u00a0P et\u00a0al (2019) OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a\u00a0germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of Oncology 30:558\u2013566","journal-title":"Annals of Oncology"},{"key":"1570_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","volume":"167","author":"K Schon","year":"2018","unstructured":"Schon\u00a0K, Tischkowitz\u00a0M (2018) Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat 167:417\u2013423","journal-title":"Breast Cancer Res Treat"},{"key":"1570_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/his.14808","volume":"82","author":"A Sokolova","year":"2023","unstructured":"Sokolova\u00a0A, Johnstone\u00a0KJ, Mccart Reed\u00a0AE et\u00a0al (2023) Hereditary breast cancer: syndromes, tumour pathology and molecular testing. Histopathology 82:70\u201382","journal-title":"Histopathology"},{"key":"1570_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","volume":"18","author":"MH Tan","year":"2012","unstructured":"Tan\u00a0MH, Mester\u00a0JL, Ngeow\u00a0J et\u00a0al (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18:400\u2013407","journal-title":"Clin Cancer Res"},{"key":"1570_CR32","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung\u00a0NM, Boughey\u00a0JC, Pierce\u00a0LJ et\u00a0al (2020) Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J\u00a0Clin Oncol 38:2080\u20132106","journal-title":"J Clin Oncol"},{"key":"1570_CR33","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung\u00a0NM, Robson\u00a0ME, Ventz\u00a0S et\u00a0al (2020) TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology 38:4274\u20134282","journal-title":"Journal of Clinical Oncology"},{"key":"1570_CR34","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt\u00a0ANJ, Garber\u00a0JE, Kaufman\u00a0B et\u00a0al (2021) Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine 384:2394\u20132405","journal-title":"New England Journal of Medicine"},{"key":"1570_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/bjc.2016.403","volume":"116","author":"E Uusitalo","year":"2017","unstructured":"Uusitalo\u00a0E, Kallionp\u00e4\u00e4\u00a0RA, Kurki\u00a0S et\u00a0al (2017) Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer 116:211\u2013217","journal-title":"Br J Cancer"},{"key":"1570_CR36","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1158\/1078-0432.CCR-09-3058","volume":"16","author":"MD Walsh","year":"2010","unstructured":"Walsh\u00a0MD, Buchanan\u00a0DD, Cummings\u00a0MC et\u00a0al (2010) Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res 16:2214\u20132224","journal-title":"Clin Cancer Res"},{"key":"1570_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/gcc.22503","volume":"57","author":"X Wang","year":"2018","unstructured":"Wang\u00a0X, Teer\u00a0JK, Tousignant\u00a0RN et\u00a0al (2018) Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. Genes Chromosomes Cancer 57:19\u201327","journal-title":"Genes Chromosomes Cancer"},{"key":"1570_CR38","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","volume":"26","author":"M Weischer","year":"2008","unstructured":"Weischer\u00a0M, Bojesen\u00a0SE, Ellervik\u00a0C et\u00a0al (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J\u00a0Clin Oncol 26:542\u2013548","journal-title":"J Clin Oncol"},{"key":"1570_CR39","volume-title":"Breast Tumours","author":"WHO Classification of Tumours","year":"2019","unstructured":"WHO Classification of Tumours (2019) Breast Tumours. International Agency for Research on Cancer, Lyon (France)"},{"key":"1570_CR40","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/jmedgenet-2019-105991","volume":"56","author":"RM Xicola","year":"2019","unstructured":"Xicola\u00a0RM, Li\u00a0S, Rodriguez\u00a0N et\u00a0al (2019) Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. J\u00a0Med Genet 56:838\u2013843","journal-title":"J Med Genet"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01570-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01570-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01570-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:02:28Z","timestamp":1787598148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-026-01570-x"}},"subtitle":["Syndrome, Pathologie, klinische Aspekte","Syndromes, pathology, clinical aspects"],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s00292-026-01570-x","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Lebeau war als Referentin und Beraterin f\u00fcr AstraZeneca, Daiichi Sankyo, MSD, Roche Pharma, Novartis, Myriad Genetics und Eurobio Scientific t\u00e4tig. Au\u00dferdem war sie als Referentin f\u00fcr Menarini-Stemline sowie als Beraterin f\u00fcr Gilead und die QuIP GmbH t\u00e4tig. R.\u00a0Schmutzler hat Honorare von AstraZeneca, Merck, MedConcept und MedTrix f\u00fcr Vortrags- oder Beratert\u00e4tigkeiten erhalten. Sie hat au\u00dferdem eine Forschungsf\u00f6rderung von Amgen erhalten und h\u00e4lt ein Patent f\u00fcr \u201eHRD Assay\u201c.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}